Article
Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.
Frontiers in immunology - 1 Jan 2020
Wu Di, Liu Yangyang, Li Xiaoting, Liu Yiying, Yang Qifan, Liu Yuting, Wu Jingjing, Tian Chen, Zeng Yulan, Zhao Zhikun, Xiao Yajie, Gu Feifei, Zhang Kai, Hu Yue, Liu Li
Abstract excerpt
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, acquired resistance to EGFR-TKIs is inevitable. Although immune checkpoint blockades (ICBs) targeting the programmed cell death 1 (PD-1)/PD-ligand (L)1 axis have achieved clinical success for many cancer types,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.